688185:SSECanSino Biologics, Inc. Class A Analysis

CanSino Biologics is trading at CNY 49.01, well below its 20‑day (50.5) and 50‑day (52.6) moving averages, signalling a bearish price momentum. The RSI of 42.8 suggests the stock is not yet oversold, while the MACD histogram is marginally positive and the signal line is flagged as bullish, indicating a potential short‑term technical bounce. However, volume is decreasing and 30‑day volatility is extremely high at 46%, reflecting weak market participation and price instability. Fundamentally, revenue grew 38.7% YoY to CNY 1.12 bn with a strong 75% gross margin, yet operating and net margins are negative, and free cash flow is deep in the red (‑CNY 351 m). The balance sheet shows CNY 2.41 bn of cash offset by CNY 1.16 bn of debt, yielding a leverage ratio of over 23 ×, and the debt‑to‑equity metric of 23.6 underscores financial strain. Valuation metrics are stark: a trailing PE of 445× versus an industry average of 30×, a price‑to‑book of 2.46, and a DCF‑derived fair value of only CNY 8.8, implying massive overvaluation. The Fear & Greed Index is at “Extreme Greed” (88.9), hinting that market sentiment may be overly optimistic despite weak fundamentals.
Given the bearish technical backdrop, high valuation multiples, negative cash generation, and elevated sector and regulatory risks, the stock appears vulnerable to a correction unless a clear catalyst—such as a successful vaccine approval—materializes.